Medizinische Hochschule Hannover
Welcome,         Profile    Billing    Logout  
 330 Trials 
1256 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lee, Keun-Wook
DisTinGuish, NCT04363801: A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer

Hourglass Oct 2023 - Mar 2024 : Q4'23/Q1'24 - Initial ORR data from DisTinGuish trial for 2L gastric cancer
Oct 2023 - Dec 2023: Initial data from part C of DisTinGuish trial in combination with tislelizumab for 1L gastric cancer
Checkmark Updated data from part B of DisTinGuish trial in combination with tislelizumab for 2L gastric cancer
Nov 2022 - Nov 2022: Updated data from part B of DisTinGuish trial in combination with tislelizumab for 2L gastric cancer
Checkmark ORR, PFS and OS data from DisTinGuish trial in combination with tislelizumab for gastroesophageal junction cancer or gastric cancer
More
Active, not recruiting
2
232
Europe, US, RoW
DKN-01 300mg, DKN-01 600mg, DKN-01 400mg, Tislelizumab 200mg, Tislelizumab 400mg, Oxaliplatin, Capecitabine 1000mg/ m2 BID, Xeloda, Leucovorin Calcium, Folinic acid, Fluorouracil
Leap Therapeutics, Inc., BeiGene
Gastric Cancer, Gastric Adenocarcinoma, GastroEsophageal Cancer
06/25
12/25
ZWI-ZW25-201, NCT03929666: A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer

Active, not recruiting
2
74
Canada, US, RoW
ZW25 (Zanidatamab), Capecitabine, Cisplatin, Fluorouracil, Leucovorin, Oxaliplatin, Bevacizumab, Gemcitabine
Jazz Pharmaceuticals
HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
11/25
10/26
NCT06062420: Phase 2 Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Recruiting
2
360
Europe, Canada, Japan, US, RoW
Dostarlimab, Belrestotug, GSK6097608
GlaxoSmithKline, iTeos Therapeutics
Neoplasms, Head and Neck
09/25
08/27
NCT04001569: AZD8186 and Paclitaxel in Advanced Gastric Cancer

Recruiting
1/2
49
RoW
AZD8186 in combination with paclitaxel
Seoul National University Bundang Hospital
Solid Tumor, Stomach Cancer
12/21
12/22
NCT04526470: Alpelisib and Paclitaxel in PIK3CA-altered Gastric Cancer

Recruiting
1/2
55
RoW
Alpelisib, Paclitaxel
Seoul National University Bundang Hospital
Solid Tumor, Stomach Cancer
06/23
12/24
BBI-20201001, NCT04278144 / 2021-006812-10: A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors

Active, not recruiting
1/2
390
Europe, US, RoW
BDC-1001, Nivolumab, Opdivo
Bolt Biotherapeutics, Inc., Bristol-Myers Squibb
HER2-positive Solid Tumors, HER2-positive Breast Cancer, HER2-positive Colorectal Cancer, HER2-positive Gastroesophageal Cancer, HER2-positive Endometrial Cancer
01/25
10/26
NCT05277168: A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS

Recruiting
1/2
83
US, RoW
SHR-A1904
Jiangsu HengRui Medicine Co., Ltd.
Advanced Solid Tumors
03/26
05/26
NCT05547906: Evaluation of the Safety and Efficacy of ASCA101 in Patients With Advanced Solid Tumors

Completed
1
18
US, RoW
ASCA101
MetaFines
Solid Tumor
02/24
02/24
NCT03821233: A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers

Active, not recruiting
1
174
Canada, US, RoW
ZW49
Zymeworks Inc.
HER2-expressing Cancers
08/25
08/25
HyperlynX, NCT06056310: Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN

Recruiting
1
40
Europe, US, RoW
Xevinapant, Debio 1143, Cisplatin, intensity-modulated radiation therapy (IMRT)
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Head and Neck Cancer
04/25
04/25
Bauersachs, Johann
NCT05697211: ORal IrON Supplementation With Ferric Maltol in Treating Iron Deficiency and Anaemia in Patients With Heart Failure (ORION-HF)

Recruiting
4
50
Europe
Ferric maltol 30 mg (Feraccru®)
Hannover Medical School, Norgine
Heart Failure, Left-sided, Anemia, Iron Deficiency
09/24
10/24
HF-REVERT, NCT05350969: Study to Assess Efficacy and Safety of CDR132L in Patients With Reduced Left Ventricular Ejection Fraction After Myocardial Infarction

Active, not recruiting
2
294
Europe, RoW
CDR132L, Placebo to CDR132L
Cardior Pharmaceuticals GmbH
Myocardial Infarction, Acute, Heart Failure, Left Sided
09/24
03/25
Arnold, Dirk
HERO-19, NCT04542408: Hamburg Edoxaban for Anticoagulation in COVID-19 Study

Completed
3
140
Europe
Anticoagulation Agents (Edoxaban and/or high dose LMWH), Low dose Low molecular weight heparin or Placebo
Universitätsklinikum Hamburg-Eppendorf
Covid19
09/22
01/23
FIRST-308, NCT05948475: Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma

Recruiting
3
200
Europe, US, RoW
Tinengotinib 8 mg, Tinengotinib 10 mg, Physician's Choice
TransThera Sciences (Nanjing), Inc.
Cholangiocarcinoma
05/26
08/26
NCT02912949 / 2014-003277-42: A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)

Recruiting
2
250
Europe, Canada, Japan, US, RoW
zenocutuzumab (MCLA-128), bispecific, MCLA-128
Merus N.V.
Solid Tumours Harboring NRG1 Fusion, NSCLC Harboring NRG1 Fusion, Pancreatic Cancer Harboring NRG1 Fusion, NRG1 Fusion
12/26
12/26
RADIANCE, NCT04230759 / 2018-003005-25: Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma. A Multicenter, Randomized, Phase II Trial of the German Anal Cancer Study Group

Active, not recruiting
2
180
Europe
Chemotherapy, all brands of 5-fluorouracil (5-FU) are allowed, all brands of Mitomycin C (MMC) are allowed, Radiation, Durvalumab, PD-L1 inhibitor
Goethe University, German Cancer Aid, AstraZeneca
Anal Cancer, Anal Carcinoma, Anal Cancer Stage III, Anal Cancer Stage II
12/26
03/27
CANFOUR, NCT03267316 / 2017-001111-36: A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors

Active, not recruiting
1/2
167
Europe
CAN04, Cisplatin, Gemcitabine, Nab-paclitaxel, Carboplatin, Pemetrexed
Cantargia AB
Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Triple Negative Breast Cancer, Colorectal Cancer
12/23
12/23
PYNNACLE, NCT04585750: The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation

Recruiting
1/2
230
Europe, US, RoW
PC14586, rezatapopt, pembrolizumab, KEYTRUDA®, MK-3475, KEYNOTE-D79, MK-3475-D79
PMV Pharmaceuticals, Inc, Merck Sharp & Dohme LLC
Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor, Lung Cancer, Ovarian Cancer, Endometrial Cancer, Prostate Cancer, Colorectal Cancer, Breast Cancer, Other Cancer, Locally Advanced, Head and Neck Cancer
03/26
07/26
CORONA Germany, NCT04659187: - Clinical Outcome and Risk in Hospitalized COVID-19 Patients - An Epidemiological Study From Germany

Recruiting
N/A
4000
Europe
Asklepios proresearch, Asklepios Kliniken GmbH & Co. KGaA
COVID-19
05/21
07/21
Gruenwald, Viktor
NCT02375204: Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors

Active, not recruiting
3
420
Europe, US, RoW
paclitaxel, Taxol, ifosfamide, Ifex®, IFOS, cisplatin, CDDP, pegylated G-CSF, G-CSF, carboplatin, Paraplatin®, CBDCA, etoposide phosphate, VePesid®, Toposar®, VP16, stem cell reinfusion
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), European Organisation for Research and Treatment of Cancer - EORTC, Movember Foundation, Institute of Cancer Research (ICR), United Kingdom, Cancer Research UK, UNICANCER, Irish Group CTI
Germ Cell Tumor, Teratoma, Choriocarcinoma, Germinoma, Mixed Germ Cell Tumor, Yolk Sac Tumor, Childhood Teratoma, Malignant Germ Cell Neoplasm, Extragonadal Seminoma, Non-seminomatous Germ Cell Tumor, Seminoma
06/24
06/24
JAVELIN Bladder Medley, NCT05327530: A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma

Recruiting
2
252
Europe, Canada, US, RoW
Avelumab, MSB0010718C, Sacituzumab Govitecan, IMMU-132, Trodelvy™, GS-0132, M6223, NKTR-255
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany; Gilead Sciences; Nektar Therapeutics
Locally Advanced or Metastatic Urothelial Carcinoma
01/25
01/25
Baumann, Ulrich
BOLD, NCT04336722 / 2019-003807-37: Efficacy and Safety of Odevixibat in Children With Biliary Atresia Who Have Undergone a Kasai HPE

Recruiting
3
245
Europe, Canada, US, RoW
Odevixibat, Placebo
Albireo
Biliary Atresia
06/26
07/26
EMBARK, NCT04524390 / 2020-000974-22: Evaluation of Maralixibat in Biliary Atresia Response Post-Kasai

Completed
2
75
Europe, US, RoW
Maralixibat, Formerly LUM001 and SHP625, Placebo
Mirum Pharmaceuticals, Inc.
Biliary Atresia
11/23
02/24
Haller, Hermann
FALCON, NCT03918447 / 2018-004651-20: A Trial of Bardoxolone Methyl in Patients With ADPKD -

Terminated
3
667
Europe, Japan, US, RoW
Bardoxolone methyl oral capsule, RTA 402, Placebo oral capsule
Reata, a wholly owned subsidiary of Biogen, Reata Pharmaceuticals, Inc., REATA PHARMACEUTICALS, INC
Autosomal Dominant Polycystic Kidney, ADPKD
08/23
08/23
ALIGN, NCT04573478: Atrasentan in Patients With IgA Nephropathy

Active, not recruiting
3
380
Europe, Canada, Japan, US, RoW
Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627, Placebo
Chinook Therapeutics U.S., Inc.
IgA Nephropathy, Immunoglobulin A Nephropathy
09/23
12/26
NCT01471834: Verification of the Efficacy and Safety of the BAROSTIM NEO System in the Treatment of Drug Resistant Hypertension

Active, not recruiting
N/A
40
Europe, Canada
BAROSTIM NEO System, XR-1 System, Neo System, Medical Management
CVRx, Inc.
High Blood Pressure
05/12
08/26
AD(H)PKD, NCT02497521: The German ADPKD Tolvaptan Treatment Registry

Recruiting
N/A
2000
Europe
University of Cologne
ADPKD (Autosomal Dominant Polycystic Kidney Disease)
11/25
12/27
Knops, Reinoud E
PRAETORIAN, NCT01296022: A PRospective, rAndomizEd Comparison of subcuTaneOous and tRansvenous ImplANtable Cardioverter Defibrillator Therapy

Active, not recruiting
N/A
850
Europe, US, RoW
Implantation of subcutaneous ICD, Implantation of transvenous ICD
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Boston Scientific Corporation
Ventricular Arrhythmias
12/19
12/23
CRT-DRIVE, NCT05327062: Cardiac Resynchronization Therapy Delivery Guided Non-Invasive Electrical and Venous Anatomy Assessment

Recruiting
N/A
150
Europe, US
CRT implantation guided by XSpline, a non-invasive electrical and venous anatomy assessment
XSpline S.p.A.
Cardiac Resynchronization Therapy, Chronic Heart Failure, Left Bundle-Branch Block
03/24
09/24
SyncAV, NCT04100148: Post-Market Trial

Active, not recruiting
N/A
1686
Europe, Canada, Japan, US, RoW
SyncAV programmed ON, Fixed AV delay
Abbott Medical Devices
Congestive Heart Failure
06/25
12/25
PRAETORIAN-DFT, NCT03495297: A Randomised Trial of S-ICD Implantation With and Without Defibrillation Testing

Active, not recruiting
N/A
965
Europe, US
ommitence of defibrillation testing
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Boston Scientific Corporation
Ventricular Arrythmia
10/24
10/24
MODULAR ATP, NCT04798768: Effectiveness of the EMPOWER™ Modular Pacing System and EMBLEM™ Subcutaneous ICD to Communicate Antitachycardia Pacing

Active, not recruiting
N/A
297
Europe, Canada, US, RoW
mCRM Therapy System, Communication of S-ICD to Leadless Cardiac Pacemaker (LCP)
Boston Scientific Corporation
Tachycardia, Ventricular, Arrhythmia, Ventricular
02/25
12/30
NCT06048731: Enlighten Study: The EV-ICD Post Approval Registry

Recruiting
N/A
1000
Europe, Canada, US, RoW
Defibrillation using EV-ICD
Medtronic
Ventricular Arrhythmia, Tachycardia
05/30
10/37
Vogel, Arndt
RAMTAS, NCT03520946 / 2017-004162-99: RAMucirumab in Combination Wth TAS102 vs. TAS102 Alone in Chemotherapy Refractory Metastatic Colorectal Cancer Patients

Active, not recruiting
3
430
Europe
Ramucirumab, TAS 102
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Eli Lilly and Company, Trium Analysis Online GmbH
Colorectal Cancer
12/23
06/24
HERIZON-GEA-01, NCT05152147 / 2021-000296-36: A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

Recruiting
3
918
Europe, Canada, Japan, RoW
Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil
Jazz Pharmaceuticals, BeiGene, Ltd.
Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma
12/24
07/25
PANOVA-3, NCT03377491: Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel

Active, not recruiting
3
556
Europe, Canada, US, RoW
NovoTTF-200T, TTFields, Gemcitabine, nab paclitaxel
NovoCure Ltd.
Pancreas Adenocarcinoma
09/24
10/24
NCT05008809: Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer (FIRE-9 - PORT / AIO-KRK-0418)

Recruiting
3
507
Europe
mFOLFOX6, Leucovorin, Oxaliplatin, 5-fluorouracil (FU), mFOLFOXIRI, Leucovorin, Oxaliplatin, 5-FU, Irinotecan
Dominik Paul Modest, German Research Foundation, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Colorectal Cancer
11/27
11/30
IMMUTACE, NCT03572582 / 2017-003553-42: Transarterial Chemoembolization in Combination With Nivolumab Performed for Intermediate Stage Hepatocellular Carcinoma

Completed
2
49
Europe
Nivolumab, TACE
AIO-Studien-gGmbH, Bristol-Myers Squibb
Carcinoma, Hepatocellular, Hepatic Carcinoma, Hepatocellular Cancer
10/21
12/21
IMMUCHEC, NCT03473574 / 2017-001538-25: Durvalumab and Tremelimumab With Gemcitabine or Gemcitabine/Cisplatin Compared to Gemcitabine/Cisplatin in CCA Patients

Checkmark Presentation of data from IMMUCHEC trial for 1L biliary tract cancer at ESMO 2022
Sep 2022 - Sep 2022: Presentation of data from IMMUCHEC trial for 1L biliary tract cancer at ESMO 2022
Completed
2
128
Europe
Durvalumab, Gemcitabine, Cisplatin, Tremelimumab
AIO-Studien-gGmbH, AstraZeneca
Cholangiocarcinoma, Gall Bladder Carcinoma, Cholangiocarcinoma Non-resectable, Gallbladder Carcinoma Non-Resectable
03/22
03/22
NCT05101629: Pembrolizumab and Lenvatinib in Patients With Advanced HCC Who Are Refractory to Atezolizumab and Bevacizumab/ IO-based Therapy

Active, not recruiting
2
32
Europe
Pembrolizumab, Keytruda, Lenvatinib Capsules, Lenvima
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Medizinische Hochschule Hannover, Germany, Prof. Dr. Arndt Vogel, Merck Sharp & Dohme LLC
Hepatocellular Carcinoma
10/24
12/24
IMMUWIN, NCT04522544: Durvalumab and Tremelimumab in Combination With Either Y-90 SIRT or DEB-TACE for Intermediate Stage HCC

Recruiting
2
55
Europe
Tremelimumab, Durvalumab, Y-90 SIRT, DEB-TACE
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, AstraZeneca, Hannover Medical School
Hepatocellular Carcinoma Non-resectable, HCC
03/25
09/25
NCT04511455: Cabozantinib for Patients With Hepatocellular Carcinoma (HCC) Refractory to First Line Treatment

Recruiting
2
45
Europe
Cabozantinib
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Ipsen
Hepatocellular Carcinoma Non-resectable, Metastatic Hepatocellular Carcinoma
06/25
12/25
NCT04238637: Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC)

Recruiting
2
50
Europe
Durvalumab, Other Name: MEDI4736, Tremelimumab, Study treatment
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, AstraZeneca
Intrahepatic Cholangiocarcinoma
12/25
12/25
NCT05174650: Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/Rearrangements

Recruiting
2
37
Europe
Atezolizumab, Tecentriq, Derazantinib, ARQ 087
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Intrahepatic Cholangiocarcinoma
12/25
08/26
NCT03645980 / 2017-002468-41: DKN-01 Inhibition in Advanced Liver Cancer

Recruiting
1/2
70
Europe
DKN-01 300 mg, DKN-01 600 mg, Sorafenib
Johannes Gutenberg University Mainz, Leap Therapeutics, Inc.
Hepatocellular Carcinoma
08/21
08/22
PLATON, NCT04484636: - Platform for Analyzing Targetable Tumor Mutations (Pilot-study)

Recruiting
N/A
400
Europe
FoundationOne®CDx and FoundationOne®Liquid
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Roche Pharma AG
Hepatocellular Cancer, Cholangiocarcinoma, Gallbladder Cancer, Pancreatic Cancer, Oesophageal Cancer, Stomach Cancer
06/24
07/24
PLATON, NCT05489250: The Network

Recruiting
N/A
1000
Europe
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Hepatocellular Cancer, Cholangiocarcinoma, Gallbladder Cancer, Pancreatic Cancer, Oesophageal Cancer, Stomach Cancer
05/32
05/32
Olsson, Karen
COMPERA, NCT01347216: / -KIDS

Recruiting
N/A
13000
Europe
Technische Universität Dresden, GWT-TUD GmbH
Pulmonary Arterial Hypertension (PAH), Pulmonary Hypertension (PH)
06/26
06/26
Bohnhorst, Bettina
FiO2-C, NCT03168516 / 2018-000453-41: Effects of Closed-loop Automatic Control of FiO2 in Extremely Preterm Infants

Active, not recruiting
3
1065
Europe, RoW
closed-loop automatic control of the inspiratory fraction of oxygen (FiO2-C)
University Hospital Tuebingen
Infant,Premature
12/26
12/26
Seibold, Frank
NCT05507203: ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

Recruiting
3
612
Europe, Canada, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
12/24
02/25
VIVID-2, NCT04232553 / 2019-002687-27: A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

Recruiting
3
778
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Crohn's Disease
01/25
12/26
NCT05535946: ABTECT - Maintenance

Recruiting
3
1050
Europe, Canada, Japan, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
01/26
06/26
LUCENT-3, NCT03519945 / 2017-004092-31: A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

Hourglass Jan 2022 - Mar 2022 : Data from LUCENT 3 trial for moderate-to-severe ulcerative colitis
Recruiting
3
1063
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Ulcerative Colitis
07/26
12/27
NCT06233461: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

Recruiting
2
268
Europe, Canada, Japan, US, RoW
TAK-279, Placebo
Takeda
Crohn's Disease
09/26
07/27
Hoglinger, Gunter
NCT05526391 / 2022-000336-28: A Study of TAK-341 in Treatment of Multiple System Atrophy

Recruiting
2
138
Europe, Japan, US
TAK-341, MEDI1341, Placebo
Takeda, AstraZeneca
Multiple System Atrophy
08/25
08/25
LUMA, NCT05348785: A Study to Assess the Safety of BIIB122 Tablets and if it Can Slow the Worsening of Early-Stage Parkinson's Disease in Participants Between the Ages of 30 and 80

Recruiting
2
640
Europe, Canada, Japan, US, RoW
BIIB122, DNL151, BIIB122-Matching Placebo
Biogen, Denali Therapeutics Inc.
Parkinson Disease
12/25
12/25
Metz, Martin
CALM-CSU, NCT06077773: Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects With Chronic Spontaneous Urticaria

Recruiting
2
114
Europe, Canada, US
Oral EP262, Placebo
Escient Pharmaceuticals, Inc
Chronic Spontaneous Urticaria
01/25
02/25
NCT05528913: Benralizumab in Chronic Prurigo - Investigating Clinical Efficacy (BICPIC)

Withdrawn
2
48
Europe
Fasenra Prefilled Syringe, Benralizumab, Matching Placebo Solution
Charite University, Berlin, Germany
Chronic Prurigo
10/23
10/23
NCT04944862: A Study of CDX-0159 in Patients With Prurigo Nodularis

Hourglass Nov 2023 - Nov 2023 : Topline data from trial for prurigo nodularis
Completed
1
24
Europe, US
CDX-0159, barzolvolimab, Normal saline
Celldex Therapeutics
Prurigo Nodularis
07/23
07/23
CALM-CIndU, NCT06050928: Phase 1b, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Chronic Inducible Urticaria

Recruiting
1
30
Europe, Canada, US
Oral EP262
Escient Pharmaceuticals, Inc
Chronic Inducible Urticaria
09/24
11/24
Chen, Jing X
NCT04766307: A New Treatment for Primary Smear-positive Pulmonary Tuberculosis With Interleukin-2

Recruiting
4
1100
RoW
Interleukin-2, IL-2
Beijing Chest Hospital
Tuberculosis, Pulmonary
12/21
12/21
NCT06406205: A Study of QLG1074 Combined With Background Therapy in Subjects With Active Lupus Nephritis

Recruiting
3
270
RoW
Voclosporin（QL1074）, Placebo
Qilu Pharmaceutical Co., Ltd.
Lupus Nephritis
06/27
06/28
NCT03430297: A Randomized, Controlled, Multi-center, Phase III Clinical Study to Investigate Recombinant Humanized PD-1 Monoclonal Antibody Injection (JS001) Versus Dacarbazine as the 1st-line Therapy for Unresectable or Metastatic Melanoma

Active, not recruiting
3
256
RoW
JS001 240mg Q2W, Dacarbazine 1000mg/m2 Q3W
Shanghai Junshi Bioscience Co., Ltd.
Metastatic Melanoma, Unresectable Melanoma
12/23
06/24
NCT05319353 / 2021-004279-15: A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Children and Teenage Transplant Recipients With CMV Infection

Recruiting
3
80
Europe, Japan, US, RoW
Maribavir, TAK-620
Takeda, Takeda Development Center Americas, Inc.
Cytomegalovirus (CMV)
11/26
11/26
NCT05602194: Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma

Recruiting
3
440
Canada, US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Calaspargase Pegol, Asparaginase (Escherichia coli Isoenzyme II), Conjugate with alpha-(((2,5-Dioxo-1-pyrrolidinyl)oxy)carbonyl)-omega-methoxypoly(oxy-1,2-ethanediyl), Asparlas, Calaspargase Pegol-mknl, EZN-2285, SC-PEG E. Coli L-Asparaginase, Succinimidyl Carbonate Monomethoxypolyethylene Glycol E. coli L-Asparaginase, Levocarnitine, Carnitor, L-carnitine, Pegaspargase, L-Asparaginase with Polyethylene Glycol, Oncaspar, Oncaspar-IV, PEG-Asparaginase, PEG-L-Asparaginase, PEG-L-Asparaginase (Enzon - Kyowa Hakko), PEGLA, Polyethylene Glycol L-Asparaginase, Polyethylene Glycol-L-Asparaginase, Quality-of-Life Assessment, Quality of Life Assessment
Children's Oncology Group
B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Acute Lymphoblastic Leukemia, BCR-ABL1-Like, Lymphoblastic Lymphoma, Mixed Phenotype Acute Leukemia, T Acute Lymphoblastic Leukemia
12/27
12/27
NCT04293562: A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Active, not recruiting
3
1400
Canada, US, RoW
Allogeneic Hematopoietic Stem Cell Transplantation, Allogeneic, Allogeneic Hematopoietic Cell Transplantation, Allogeneic Stem Cell Transplantation, HSC, HSCT, Stem Cell Transplantation, Allogeneic, Asparaginase, ASP-1, Asparaginase II, Asparaginase-E.Coli, Colaspase, Elspar, Kidrolase, L-Asnase, L-ASP, L-Asparaginase, L-Asparagine Amidohydrolase, Laspar, Lcf-ASP, Leucogen, Leunase, MK-965, Paronal, Re-82-TAD-15, Serasa, Spectrila, Asparaginase Erwinia chrysanthemi, Asparaginase Erwinia Chrysanthemi (Recombinant)-rywn, Asparaginase Erwinia chrysanthemi-rywn, Crisantaspase, Crisantaspase Biobetter JZP-458, Crisantaspasum, Erwinase, Erwinaze, JZP 458, JZP-458, JZP458, PF743, RC-P JZP-458, Recombinant Asparaginase erwinia chrysanthemi JZP-458, Recombinant Crisantaspase JZP-458, Recombinant Erwinia asparaginase JZP-458, Rylaze, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Cogstate Assessment Battery, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Daunorubicin Hydrochloride, Cerubidin, Cerubidine, Cloridrato de Daunorubicina, Daunoblastin, Daunoblastina, Daunoblastine, Daunomycin Hydrochloride, Daunomycin, hydrochloride, Daunorubicin.HCl, Daunorubicini Hydrochloridum, FI-6339, Ondena, RP-13057, Rubidomycin Hydrochloride, Rubilem, Dexrazoxane Hydrochloride, Cardioxane, Totect, Zinecard, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP 16213, VP-16, VP-16-213, VP16, Fludeoxyglucose F-18, 18FDG, FDG, Fludeoxyglucose (18F), fludeoxyglucose F 18, Fludeoxyglucose F18, Fluorine-18 2-Fluoro-2-deoxy-D-Glucose, Fluorodeoxyglucose F18, Gemtuzumab Ozogamicin, Calicheamicin-Conjugated Humanized Anti-CD33 Monoclonal Antibody, CDP-771, CMA-676, gemtuzumab, hP67.6-Calicheamicin, Mylotarg, WAY-CMA-676, Gilteritinib Fumarate, ASP-2215 Hemifumarate, ASP2215 Hemifumarate, Gilteritinib Hemifumarate, Xospata, Liposome-encapsulated Daunorubicin-Cytarabine, CPX-351, Cytarabine and Daunorubicin Liposomal, Cytarabine-Daunorubicin Liposome for Injection, Daunorubicin and Cytarabine (Liposomal), Liposomal AraC-Daunorubicin CPX-351, Liposomal Cytarabine-Daunorubicin, Liposome-encapsulated Combination of Daunorubicin and Cytarabine, Vyxeos, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Methotrexate, Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, CL 14377, CL-14377, Emtexate, Emthexat, Emthexate, Farmitrexat, Fauldexato, Folex, Folex PFS, Lantarel, Ledertrexate, Lumexon, Maxtrex, Medsatrexate, Metex, Methoblastin, Methotrexate LPF, Methotrexate Methylaminopterin, Methotrexatum, Metotrexato, Metrotex, Mexate, Mexate-AQ, MTX, Novatrex, Rheumatrex, Texate, Tremetex, Trexeron, Trixilem, WR-19039, Mitoxantrone Hydrochloride, CL 232315, DHAD, DHAQ, Dihydroxyanthracenedione Dihydrochloride, Mitoxantrone Dihydrochloride, Mitoxantroni Hydrochloridum, Mitozantrone Hydrochloride, Mitroxone, Neotalem, Novantrone, Onkotrone, Pralifan, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Therapeutic Hydrocortisone, Aeroseb-HC, Barseb HC, Barseb-HC, Cetacort, Cort-Dome, Cortef, Cortenema, Cortifan, Cortisol, Cortispray, Cortril, Dermacort, Domolene, Eldecort, Hautosone, Heb-Cort, Hydrocortisone, Hydrocortone, Hytone, Komed-HC, Nutracort, Proctocort, Rectoid
Children's Oncology Group, National Cancer Institute (NCI)
Acute Myeloid Leukemia
09/27
09/27
NACI-CERV-003, NCT06288373: Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC

Not yet recruiting
2/3
440
RoW
Camrelizumab, Cisplatin, Nab paclitaxel, Radical surgery, external beam radiation therapy (EBRT) + brachytherapy
Tongji Hospital, Southwest Hospital, China, Women Hospital, School of Medicine, Zhejiang University, Anhui Provincial Cancer Hospital, Sichuan Cancer Hospital and Research Institute, Qilu Hospital of Shandong University, Beijing Friendship Hospital, Tianjin Medical University General Hospital, West China Second University Hospital, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Xiangya Hospital of Central South University, Gansu Provincial Maternal and Child Health Care Hospital, Zhejiang Cancer Hospital, Shengjing Hospital
Cervical Cancer, Locally Advanced Cervical Cancer, Concurrent Chemoradiotherapy, Neoadjuvant Chemoimmunotherapy
03/31
03/31
NCT04910126: Camrelizumab Plus Doxorubicin for the First Line Treatment of Adcanced Soft Tissue Sarcoma

Recruiting
2
84
RoW
Camrelizumab, C, Adriamycin, A
Wuhan Union Hospital, China
Soft Tissue Sarcoma, Neoplasms, Connective and Soft Tissue, Sarcoma Metastatic, Sarcoma,Soft Tissue
01/23
11/23
NCT05114603: A Phase II Clinical Trial to Evaluate HLX208 in Advanced Melanoma Patients With BRAF V600 Mutation

Recruiting
2
30
RoW
HLX208
Shanghai Henlius Biotech
Advanced Melanoma
08/23
08/24
NACI-CERV-005, NCT06289062: Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical Cancer

Not yet recruiting
2
40
RoW
Camrelizumab, Cisplatin, Nab paclitaxel, biopsy
Tongji Hospital, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Women Hospital, School of Medicine, Zhejiang University, Third Military Medical University, Beijing Friendship Hospital, Sichuan Cancer Hospital and Research Institute, Tianjin Medical University, West China Second University Hospital, Xiangya Hospital of Central South University, Qilu Hospital of Shandong University, Gansu Cancer Hospital, Zhejiang Cancer Hospital, Shengjing Hospital, Anhui Provincial Cancer Hospital
Cervical Cancer, Neoadjuvant Chemoimmunotherapy, Fertility Preservation
12/25
12/30
NACI-CERV-002, NCT06288360: Neoadjuvant Immunochemotherapy in PD-L1-negative LACC

Not yet recruiting
2
40
RoW
Camrelizumab, SHR-1210, Paclitaxel-albumin, Injectable paclitaxel (albumin bound), Cisplatin, Cisplatin injection, radical surgery
Tongji Hospital, Southwest Hospital, China, Women Hospital, School of Medicine, Zhejiang University, Anhui Provincial Cancer Hospital, Sichuan Cancer Hospital and Research Institute, Gansu Provincial Maternal and Child Health Care Hospital, Beijing Friendship Hospital, Tianjin Medical University General Hospital, Xiangya Hospital of Central South University, West China Second University Hospital, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Zhejiang Cancer Hospital, Shengjing Hospital, Qilu Hospital of Shandong University
Cervical Cancer, Locally Advanced Cervical Cancer, PD-L1 Negative, Neoadjuvant Chemoimmunotherapy
12/25
12/30
NCT06289751: Neoadjuvant Chemoimmunotherapy and Extrafascial Hysterectomy for IB2 Cervical Cancer

Not yet recruiting
2
50
RoW
Cadonilimab, Cadonilimab Injection, Paclitaxel-albumin, Injectable paclitaxel (albumin bound), Cisplatin, Cisplatin injection, Extrafascial hysterectomy
Tongji Hospital, The First Affiliated Hospital of China University of Science and Technology (Anhui Provincial), Women Hospital, School of Medicine, Zhejiang University, Southwest Hospital, China, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Sichuan Cancer Hospital and Research Institute, Qilu Hospital of Shandong University, Beijing Friendship Hospital, Tianjin Medical University, West China Second University Hospital, Xiangya Hospital of Central South University, Gansu Provincial Maternal and Child Health Care Hospital, Zhejiang Cancer Hospital, Shengjing Hospital
Cervical Cancer, Neoadjuvant Chemoimmunotherapy, Radical Hysterectomy, Fertility Preservation
03/26
01/31
NCT06367075: A Trial of Cadonilimab With Adriamycin in Patients With Advanced Soft Tissue Sarcoma

Not yet recruiting
2
53
NA
Cadonilimab, AK104, Adriamycin, Doxorubicin
Wuhan Union Hospital, China, Sun Yat-sen University, Xiangya Hospital of Central South University, Yunnan Cancer Hospital, The Affiliated Hospital Of Guizhou Medical University, First Affiliated Hospital of Guangxi Medical University
Advanced Soft-tissue Sarcoma
03/27
03/29
NCT05046314: A Clinical Study of TK216 in Patients With Relapsed or Refractory Ewing's Sarcoma

Recruiting
2
30
RoW
TK216+Vincristin
Shanghai Pharmaceuticals Holding Co., Ltd
Sarcoma, Ewing
09/25
12/25
ARTEMIS-002, NCT05830123: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas

Recruiting
2
170
RoW
HS-20093
Hansoh BioMedical R&D Company
Osteosarcoma, Sarcoma
12/25
12/27
NCT05761171: A Study of SNDX-5613 in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia

Recruiting
2
78
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Calaspargase Pegol, Asparaginase (Escherichia coli Isoenzyme II), Conjugate with alpha-(((2,5-Dioxo-1-pyrrolidinyl)oxy)carbonyl)-omega-methoxypoly(oxy-1,2-ethanediyl), Asparlas, Calaspargase Pegol-mknl, EZN-2285, SC-PEG E. Coli L-Asparaginase, Succinimidyl Carbonate Monomethoxypolyethylene Glycol E. coli L-Asparaginase, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Echocardiography, EC, Fludarabine Phosphate, 2-F-ara-AMP, 9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-, Beneflur, Fludara, SH T 586, Hydrocortisone Sodium Succinate, (11beta)-21-(3-Carboxy-1-oxopropyl)-11,17-dihydroxypregn-4-ene-3,20-dione, Monosodium Salt, A-Hydrocort, Buccalsone, Corlan, Cortisol Sodium Succinate, Cortop, Efcortelan, Emergent-EZ, Flebocortid, Hidroc Clora, Hycorace, Hydro-Adreson, Hydrocort, Hydrocortisone 21-Sodium Succinate, Hydrocortisone Na Succinate, Kinogen, Nordicort, Nositrol, Sinsurrene, Sodium hydrocortisone succinate, Solu-Cortef, Solu-Glyc, Lumbar Puncture, LP, Spinal Tap, Methotrexate, Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, CL 14377, CL-14377, Emtexate, Emthexat, Emthexate, Farmitrexat, Fauldexato, Folex, Folex PFS, Lantarel, Ledertrexate, Lumexon, Maxtrex, Medsatrexate, Metex, Methoblastin, Methotrexate LPF, Methotrexate Methylaminopterin, Methotrexatum, Metotrexato, Metrotex, Mexate, Mexate-AQ, MTX, Novatrex, Rheumatrex, Texate, Tremetex, Trexeron, Trixilem, WR-19039, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Prednisolone, (11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione, .delta.1-Hydrocortisone, Adnisolone, Aprednislon, Capsoid, Cortalone, Cortisolone, Dacortin H, Decaprednil, Decortin H, Delta(1)Hydrocortisone, Delta- Cortef, Delta-Cortef, Delta-Diona, Delta-F, Delta-Phoricol, Delta1-dehydro-hydrocortisone, Deltacortril, Deltahydrocortisone, Deltasolone, Deltidrosol, Dhasolone, Di-Adreson-F, Dontisolon D, Estilsona, Fisopred, Frisolona, Gupisone, Hostacortin H, Hydeltra, Hydeltrasol, Klismacort, Kuhlprednon, Lenisolone, Lepi-Cortinolo, Linola-H N, Linola-H-Fett N, Longiprednil, Metacortandralone, Meti Derm, Meticortelone, Opredsone, Panafcortelone, Precortisyl, Pred-Clysma, Predeltilone, Predni-Coelin, Predni-Helvacort, Prednicortelone, Prednisolonum, Prelone, Prenilone, Sterane, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Revumenib, Menin-Mixed Lineage Leukemia Protein-Protein Interaction Inhibitor SNDX-5613, Menin-MLL Inhibitor SNDX-5613, Menin-MLL Interaction Inhibitor SNDX-5613, SNDX 5613, SNDX-5613, SNDX5613, Vincristine Sulfate, Kyocristine, Leurocristine Sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate
Children's Oncology Group
Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia Due to Lineage Switch From Acute Leukemia of Ambiguous Lineage, Recurrent Acute Myeloid Leukemia Due to Lineage Switch From B Acute Lymphoblastic Leukemia, KMT2A-Rearranged, Recurrent Acute Myeloid Leukemia Due to Lineage Switch From Mixed Phenotype Acute Leukemia, Recurrent Mixed Phenotype Acute Leukemia, Refractory Acute Leukemia of Ambiguous Lineage, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia Due to Lineage Switch From Acute Leukemia of Ambiguous Lineage, Refractory Acute Myeloid Leukemia Due to Lineage Switch From B Acute Lymphoblastic Leukemia, KMT2A-Rearranged, Refractory Acute Myeloid Leukemia Due to Lineage Switch From Mixed Phenotype Acute Leukemia, Refractory Mixed Phenotype Acute Leukemia
12/27
12/27
NCT04203316: Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation

Recruiting
2
10
Canada, US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Enasidenib, AG-221, CC-90007 Free Base, Enasidenib Mesylate, 2-Methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol Methanesulfonate, 2-Propanol, 2-Methyl-1-((4-(6-(trifluoromethyl)-2-pyridinyl)-6-((2-(trifluoromethyl)-4-pyridinyl)amino)-1,3,5-triazin-2-yl)amino)-, Methanesulfonate (1:1), AG-221 Mesylate, CC-90007, Enasidenib Methanesulfonate, Idhifa
Children's Oncology Group, National Cancer Institute (NCI)
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
12/30
12/30
NCT04390737: Evaluate the Safety and Clinical Activity of HH2853

Recruiting
1/2
254
US, RoW
HH2853 Tablets
Haihe Biopharma Co., Ltd.
FL Lymphoma, Epithelioid Sarcoma, Peripheral T Cell Lymphoma, Advanced Solid Tumor
12/25
12/25
AUGMENT-101, NCT04065399 / 2020-004104-34: A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

Calendar Jan 2024 - Dec 2024: Market entry for acute leukemias
Hourglass Feb 2024 - Mar 2024 : Q1'24 - PDUFA date from FDA for R/R KMT2Ar acute leukemia
Jul 2023 - Sep 2023: Data from AUGMENT-101 trial for r/r AML
Checkmark Updated data from P1 portion of P1/2 AUGMENT-101 trial for AML
Dec 2022 - Dec 2022: Updated data from P1 portion of P1/2 AUGMENT-101 trial for AML
More
Recruiting
1/2
413
Europe, Canada, US, RoW
revumenib, SNDX-5613, cobicistat
Syndax Pharmaceuticals, Syndax Pharmaceuticals, Inc
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Lineage Acute Leukemia, Mixed Phenotype Acute Leukemia, Acute Leukemia of Ambiguous Lineage
12/24
12/24
NCT05944224: A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors.

Recruiting
1/2
63
RoW
SPH4336, Cadonilimab
Shanghai Pharmaceuticals Holding Co., Ltd
Advanced Solid Tumors
05/25
12/25
APAL2020SC, NCT04726241: The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

Recruiting
1/2
960
Canada, US, RoW
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection
LLS PedAL Initiative, LLC, Children's Oncology Group, National Cancer Institute (NCI)
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia Post Cytotoxic Therapy, Juvenile Myelomonocytic Leukemia, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome, Myelodysplastic Syndrome Post Cytotoxic Therapy, Myeloid Leukemia Associated With Down Syndrome
12/26
12/26
NCT05798546: Treatment of Advanced Solid Tumors With Neo-T(GI-NeoT-02)

Recruiting
1
21
RoW
Neo-T, Neoantigen targeting T cells Suspension for Intravenous Infusion, Cyclophosphamide, CTX, Fludarabine, FDR, Interleukin-2, IL-2
BGI, China, Wuhan Union Hospital, China
Solid Tumor
09/23
09/24
NCT04773951: A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of JS004 in Advanced Solid Tumors

Recruiting
1
156
RoW
JS004, a recombinant humanized, IgG4κ monoclonal antibody (mAb) specific to B- and T-lymphocyte attenuator (BTLA); Toripalimab Injection
Shanghai Junshi Bioscience Co., Ltd.
Melanoma, Renal Carcinoma, Urothelial Carcinoma
02/24
08/24
NCT04936178: A Study of NB003 in Patients With Advanced Malignancies

Recruiting
1
258
Europe, US, RoW
NB003 tablets
Ningbo Newbay Technology Development Co., Ltd
Advanced Solid Tumor
07/25
12/25
NCT04033627: TCDαβ/CD45RA Haploidentical Transplantation in Children With Leukemia

Recruiting
N/A
30
RoW
In Vitro T cells depletion using CliniMCAS system
Shanghai Children's Medical Center, Nanfang Hospital of Southern Medical University, Children's Hospital Of Soochow University, Chinese University of Hong Kong, Miltenyi Biomedicine GmbH
Relapsed Pediatric ALL, Acute Graft-Versus-Host Disease (Gvhd) Grade IV (Diagnosis), Relapsed Pediatric AML
07/22
05/24
HELP-PPCI, NCT05329155: Early Administration of Heparin at FMC for PPCI of STEMI Patients

Active, not recruiting
N/A
1144
RoW
Heparin Sodium Injection
Renmin Hospital of Wuhan University, Xiangyang Central Hospital, The Central Hospital of Enshi Tujia And Miao Autonomous Prefecture, Wuhan Central Hospital, People's Hospital of Jingshan, Chibi General Hospital, Xianning Central Hospital, Suizhou Central Hospital, Yichang Central People's Hospital, People's Hospital of Tongcheng, Ezhou Central Hospital, Xiantao First People's Hospital, Songzi People's Hospital, Anlu People's Hospital, Caidian People's Hospital, Jiangxia First People's Hospital, Jingzhou Central Hospital, Hubei Zhongshan Hospital, Guoyao Dongfeng General Hospital, Wuhan Puren Hospital, Shiyan People's Hospital, General Hospital of Yangtze River shipping, Fifth Hospital in Wuhan, CR & WISCO General Hospital, Xishui People's Hospital, Jiangling People's Hospital, Wuhan Third Hospital, Laohekou First Hospital, Huanggang Central Hospital, Wuhan No.1 Hospital, Wuhan Hanyang Hospital, Wuxue First People's Hospital, Tianmen First People's Hospital, Xianning First People's Hospital, Wuhan No.6 Hospital, Wuhan Hospital of Traditional Chinese Medicine
STEMI, Primary PCI
08/23
08/24
NCT06423131: Prospective Clinical Trial for Children With TCRαβ Depleted vs Traditional Haplo Identicle HSCT

Recruiting
N/A
110
RoW
TCRαβ Depleted haploidentical HCT
Sijia Gu
Graft-Versus-Host Disease, Hematopoietic Stem Cell Transplantation, Child, Only, Haploidentical Hematopoietic Stem Cell Transplantation
03/27
03/28
NCT04433455: Influencing Factors of Cerebrovascular Disease and Cognition in Hemodialysis Patients

Recruiting
N/A
20
RoW
Huashan Hospital
Hemodialysis, Cognitive Impairment, Cerebrovascular Disorders
05/25
05/25
Eder, Matthias
NCT04232241: Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia

Recruiting
2
440
Europe, RoW
Allogeneic Stem Cell Transplantation
Universitätsklinikum Hamburg-Eppendorf, DKMS Stiftung Leben Spenden, Clinical Trial Center North (CTC North GmbH & Co. KG)
Acute Myeloid Leukemia in Remission, Acute Lymphoblastic Leukemia in Remission, Myelodysplastic Syndromes
11/22
11/24
Stadler, Michael
Predictor2, NCT03887156: Evaluation of a Donor Testing Kit for the Prediction of AGVHD in Patient Receiving a Peripheral Blood Stem Cell Allograft

Recruiting
2/3
227
Europe
Ex vivo capacities of CD4neg INkT expansion of the peripheral blood donor with the Predictor test
Assistance Publique - Hôpitaux de Paris, SATT, SNC Graft Versus Host Disease, Imagine Institute, Axonal-Biostatem, CERBA laboratory
Acute Myeloid Leukemia in Remission, Lymphoma in Remission, Non-progressive Myeloproliferative Syndrome, Myelodysplasia With Stable Blasts is Cell Number and < 10% of Blastocysts, Acute Leukemia Biphenotypic in Remission, Acute Lymphoblastic Leukemia
03/23
03/23
NCT04630353: A Study HB-201 in Patients With Newly Diagnosed HPV16+ Oropharynx or Locally Advanced Cervical Cancer

Terminated
1
10
US
HB-201 IV
Hookipa Biotech GmbH
HPV 16+ Confirmed Oropharynx Cancer and Cervical Cancer
11/23
11/23
Schneider, Julia
VANTAGE, NCT05050136: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis

Recruiting
2
180
Europe, US, RoW
Volixibat, SHP626, Placebo
Mirum Pharmaceuticals, Inc.
Primary Biliary Cholangitis, PBC
12/25
12/25
Lee, Yoo Jin
NCT02584478: Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)

Active, not recruiting
3
294
Europe, US, RoW
AL3818, Anlotinib Hydrochloride, Anlotinib, Catequentinib, Paclitaxel, Pegylated Liposomal Doxorubicin (PLD), Topotecan, Daily Topotecan, Weekly Topotecan, Carboplatin, Paraplatin, Taxol
Advenchen Laboratories, LLC
Endometrial Carcinoma, Ovarian Carcinoma, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma, Cervical Carcinoma
10/24
12/24
VIVID-2, NCT04232553 / 2019-002687-27: A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

Recruiting
3
778
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Crohn's Disease
01/25
12/26
NCT06233461: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

Recruiting
2
268
Europe, Canada, Japan, US, RoW
TAK-279, Placebo
Takeda
Crohn's Disease
09/26
07/27
SOLUTION, NCT04370496: Safety of Minimally Invasive Surgery Using Endoscopic Stapler in Early Stage Cervical Cancer Patients

Recruiting
2
124
RoW
Minimally invasive surgery using endoscopic stapler
Seoul National University Hospital, Johnson & Johnson
Cervical Cancer, Cervical Cancer Stage IB1, Minimally Invasive Surgery
12/28
12/28
NCT05182996: Perceptions and Barriers About Cessation of Smoking Among IBD Patients

Recruiting
N/A
350
RoW
smoking education
Keimyung University Dongsan Medical Center
Smoking, Inflammatory Bowel Diseases
03/22
10/22
LARK, NCT02984566: Liver Ablative Radiotherapy Utilising Kilovoltage Intrafraction Monitoring (KIM)

Active, not recruiting
N/A
32
RoW
Kilovoltage Intrafraction Monitoring
University of Sydney
Liver Cancer
07/25
12/25
NCT04900051: Clinical Efficacy and Safety of Fecal Microbiota Transplantation

Recruiting
N/A
100
RoW
Keimyung University Dongsan Medical Center
Fecal Microbiota Transplantation
12/23
12/23
Qu, Xiujuan
ENREACH-PDAC-01, NCT05149326: KN046 in Subjects With Advanced Pancreatic Ductal Adenocarcinoma.

Active, not recruiting
3
408
RoW
KN046, placebo
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Advanced Pancreatic Ductal Adenocarcinoma
04/24
08/24
 

Download Options